Search Results Search Sort by RelevanceMost Recent Case and Commentary Jul 2003 Drug Company Sponsorship of Clinical Conferences, Commentary 1 Robert Goodman, MD Virtual Mentor. 2003;5(7):239-241. doi: 10.1001/virtualmentor.2003.5.7.ccas1-0307. Case and Commentary Jul 2003 Drug Company Sponsorship of Clinical Conferences, Commentary 2 Ashley Wazana, MD Virtual Mentor. 2003;5(7):242-246. doi: 10.1001/virtualmentor.2003.5.7.ccas1-0307. Case and Commentary Jul 2003 Clinician and Researcher, Commentary 1 Timothy F. Murphy, PhD Virtual Mentor. 2003;5(7):247-250. doi: 10.1001/virtualmentor.2003.5.7.ccas2-0307. Case and Commentary Jul 2003 Clinician and Researcher, Commentary 2 Matthew Wynia, MD Virtual Mentor. 2003;5(7):251-254. doi: 10.1001/virtualmentor.2003.5.7.ccas2-0307. In the Literature Jul 2003 Financial Conflicts of Interest in Biomedical Research Jeremy Spevick Virtual Mentor. 2003;194-196. doi: 10.1001/virtualmentor.2003.5.7.jdsc1-0307. Medical Education Jul 2003 Commercial Support for Continuing Medical Education Murray Kopelow, MD Virtual Mentor. 2003;5(7):255-259. doi: 10.1001/virtualmentor.2003.5.7.medu1-0307. Policy Forum Jul 2003 Undergraduate and Graduate Medical Education and the Pharmaceutical Industry Greg E. Manship, MDiv, MA Virtual Mentor. 2003;5(7):268-272. doi: 10.1001/virtualmentor.2003.5.7.pfor1-0307. Policy Forum Jul 2003 The PhRMA Code: A New Roadmap for Industry-Physician Interactions Michael Scott Labson, Esq Virtual Mentor. 2003;5(7):273-275. doi: 10.1001/virtualmentor.2003.5.7.pfor2-0307. Policy Forum Oct 2003 Psychotropic Medications and Criminal Defendants Robert M. Wettstein, MD Virtual Mentor. 2003;5(10):455-459. doi: 10.1001/virtualmentor.2003.5.10.pfor1-0310 Case and Commentary Jun 2016 Medication Refusal in Schizophrenia: Preventive and Reactive Ethical Considerations James Sabin, MD Overriding a proxy decision maker’s refusal of medication for a psychotic patient is justified when the patient poses a danger to himself or others. AMA J Ethics. 2016;18(6):572-578. doi: 10.1001/journalofethics.2016.18.6.ecas1-1606. Pagination First page « First Previous page ‹ Previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page Next › Last page Last »
Case and Commentary Jul 2003 Drug Company Sponsorship of Clinical Conferences, Commentary 1 Robert Goodman, MD Virtual Mentor. 2003;5(7):239-241. doi: 10.1001/virtualmentor.2003.5.7.ccas1-0307.
Case and Commentary Jul 2003 Drug Company Sponsorship of Clinical Conferences, Commentary 2 Ashley Wazana, MD Virtual Mentor. 2003;5(7):242-246. doi: 10.1001/virtualmentor.2003.5.7.ccas1-0307.
Case and Commentary Jul 2003 Clinician and Researcher, Commentary 1 Timothy F. Murphy, PhD Virtual Mentor. 2003;5(7):247-250. doi: 10.1001/virtualmentor.2003.5.7.ccas2-0307.
Case and Commentary Jul 2003 Clinician and Researcher, Commentary 2 Matthew Wynia, MD Virtual Mentor. 2003;5(7):251-254. doi: 10.1001/virtualmentor.2003.5.7.ccas2-0307.
In the Literature Jul 2003 Financial Conflicts of Interest in Biomedical Research Jeremy Spevick Virtual Mentor. 2003;194-196. doi: 10.1001/virtualmentor.2003.5.7.jdsc1-0307.
Medical Education Jul 2003 Commercial Support for Continuing Medical Education Murray Kopelow, MD Virtual Mentor. 2003;5(7):255-259. doi: 10.1001/virtualmentor.2003.5.7.medu1-0307.
Policy Forum Jul 2003 Undergraduate and Graduate Medical Education and the Pharmaceutical Industry Greg E. Manship, MDiv, MA Virtual Mentor. 2003;5(7):268-272. doi: 10.1001/virtualmentor.2003.5.7.pfor1-0307.
Policy Forum Jul 2003 The PhRMA Code: A New Roadmap for Industry-Physician Interactions Michael Scott Labson, Esq Virtual Mentor. 2003;5(7):273-275. doi: 10.1001/virtualmentor.2003.5.7.pfor2-0307.
Policy Forum Oct 2003 Psychotropic Medications and Criminal Defendants Robert M. Wettstein, MD Virtual Mentor. 2003;5(10):455-459. doi: 10.1001/virtualmentor.2003.5.10.pfor1-0310
Case and Commentary Jun 2016 Medication Refusal in Schizophrenia: Preventive and Reactive Ethical Considerations James Sabin, MD Overriding a proxy decision maker’s refusal of medication for a psychotic patient is justified when the patient poses a danger to himself or others. AMA J Ethics. 2016;18(6):572-578. doi: 10.1001/journalofethics.2016.18.6.ecas1-1606.